Evidence map›Paper›PMID 36042131›Full record

ReviewPharmacological reports : PR2022

Contribution of hyperglycemia-induced changes in microglia to Alzheimer's disease pathology.

Maricarmen Hernández-Rodríguez, Cecilia Flores Clemente, Martha Edith Macías-Pérez, Rolando Alberto Rodríguez-Fonseca, M Inés Nicolás Vázquez, Joel Martínez, Rene Miranda Ruvalcaba, Martín Martínez Rosas, Elvia Mera Jiménez

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmacological reports : PR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Regulatory Role of lncRNAInternational journal of molecular sciences · 2025
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Maricarmen Hernández-RodríguezLaboratorio de Cultivo Celular, Sección de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Salvador Diaz Mirón S/N, 11340, Mexico City, Mexico. dra.hernandez.ipn@gmail.com.ORCID http://orcid.org/0000-0001-9371-1095
Cecilia Flores ClementeLaboratorio de Cultivo Celular, Sección de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Salvador Diaz Mirón S/N, 11340, Mexico City, Mexico.ORCID http://orcid.org/0000-0002-2437-9962
Martha Edith Macías-PérezUnidad de Investigación Biomédica de Zacatecas (UIBMZ) del Instituto Mexicano del Seguro Social (IMSS), Alameda Trinidad García de La Cadena, 98000, Zacatecas, Mexico.ORCID http://orcid.org/0000-0001-9465-4897
Rolando Alberto Rodríguez-FonsecaUnidad de Investigación Biomédica de Zacatecas (UIBMZ) del Instituto Mexicano del Seguro Social (IMSS), Alameda Trinidad García de La Cadena, 98000, Zacatecas, Mexico.ORCID http://orcid.org/0000-0001-8655-7122
M Inés Nicolás VázquezQuímica Inorgánica-Orgánica del Departamento de Ciencias Químicas, Facultad de Estudios Superiores Cuautitlán Campo 1, Universidad Nacional Autónoma de México, Av. Primero de Mayo S/N, 54740, Estado de México, Mexico.ORCID http://orcid.org/0000-0003-0722-5045
Joel MartínezQuímica Inorgánica-Orgánica del Departamento de Ciencias Químicas, Facultad de Estudios Superiores Cuautitlán Campo 1, Universidad Nacional Autónoma de México, Av. Primero de Mayo S/N, 54740, Estado de México, Mexico.ORCID http://orcid.org/0000-0002-6683-6738
Rene Miranda RuvalcabaQuímica Inorgánica-Orgánica del Departamento de Ciencias Químicas, Facultad de Estudios Superiores Cuautitlán Campo 1, Universidad Nacional Autónoma de México, Av. Primero de Mayo S/N, 54740, Estado de México, Mexico.ORCID http://orcid.org/0000-0002-1979-5590
Martín Martínez RosasDepartamento de Fisiología, Instituto Nacional de Cardiología "Ignacio Chávez", Juan Badiano 1, 14080, Mexico City, Mexico.ORCID http://orcid.org/0000-0001-5687-0345
Elvia Mera JiménezLaboratorio de Cultivo Celular, Sección de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Salvador Diaz Mirón S/N, 11340, Mexico City, Mexico. elviamj@gmail.com.ORCID http://orcid.org/0000-0002-7821-4012
Instituto Politécnico Nacional · MXMexican Social Security Institute · MXUniversidad Nacional Autónoma de México · MXAutonomous University of San Luis Potosí · MXInstituto Nacional de Cardiología · MX

Funding

Consejo Nacional de Ciencia y Tecnología 320862PAPIIT UNAM IN212421Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional 20221071Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional 20221072
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative condition characterized by cognitive and functional impairments. The investigation of AD has focused on the formation of senile plaques, composed mainly by amyloid β (Aβ) peptide, and neurofibrillary tangles (NFTs) in the brain. Senile plaques and NFTs cause the excessive recruitment and activation of microglia, thus generating neuroinflammation and neuronal damage. Among the risk factors for the development of AD, diabetes has increasingly attracted attention. Hyperglycemia, the fundamental characteristic of diabetes, is involved in several mechanisms that give rise to microglial overactivation, resulting in neuronal damage and cognitive impairment. Indeed, various studies have identified the correlation between diabetes and AD. The aim of this review is to describe various mechanisms of the hyperglycemia-induced overactivation of microglia, which leads to neuroinflammation and neuronal damage and consequently contributes to the pathology of AD. The disruption of the regulation of microglial activity by hyperglycemia occurs through many mechanisms, including a greater production of reactive oxygen species (ROS) and glycation end products (AGEs), and a decrease in the elimination of Aβ. The future direction of research on the relation between hyperglycemia and AD is addressed, such as the importance of determining whether the hyperglycemia-induced harmful effects on microglial activity can be reversed or attenuated if blood glucose returns to a normal level.

Indexed as

Alzheimer DiseaseHyperglycemiaAmyloid beta-PeptidesBlood GlucoseHumansMicrogliaPlaque, AmyloidReactive Oxygen SpeciesAmyloid beta-PeptidesBlood GlucoseReactive Oxygen SpeciesAlzheimer’s diseaseAmyloid betaDiabetesHyperglycemiaMicrogliaTau protein

Identifiers

PMID36042131
OpenAlexW4293708207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.